Cipher Pharmaceuticals Inc.

CPHR-Q

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about CPHR-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
December 30, 2019
A specialty pharma company. Their biggest product is a dermatology product. They had a failed US expansion but that is gone now. They finally reported a decent quarter. The company is up for sale. A product was just approved by Health Canada. He thinks it is easily worth more than $2 a share. (Analysts’ price target is $2.31)
Show full opinionHide full opinion
A specialty pharma company. Their biggest product is a dermatology product. They had a failed US expansion but that is gone now. They finally reported a decent quarter. The company is up for sale. A product was just approved by Health Canada. He thinks it is easily worth more than $2 a share. (Analysts’ price target is $2.31)
HOLD
HOLD
May 31, 2019
It has been a disaster for the past few years. It has collected royalties on drugs for years. It trades at 4 times earnings. He believes it to be a great take over target. However, the Board and the larger shareholders are not interested in that. It is too cheap to ignore.
Show full opinionHide full opinion
It has been a disaster for the past few years. It has collected royalties on drugs for years. It trades at 4 times earnings. He believes it to be a great take over target. However, the Board and the larger shareholders are not interested in that. It is too cheap to ignore.
TOP PICK
TOP PICK
December 20, 2018
Really oversold, yet deep value. Should get a good bounce in January. A specialty pharma maker with almost zero economic exposure. (Analysts’ price target is $5.06)
Show full opinionHide full opinion
Really oversold, yet deep value. Should get a good bounce in January. A specialty pharma maker with almost zero economic exposure. (Analysts’ price target is $5.06)
PAST TOP PICK
PAST TOP PICK
August 25, 2015

(A Top Pick Oct 24/14. Down 33.71%.) They were in a bit of a jam in that they had one particularly strong product but didn’t have a sales force, so they acquired a company in the US to get them a sales force. He could see this was going to drop their earnings, so he sold his position.

Show full opinionHide full opinion

(A Top Pick Oct 24/14. Down 33.71%.) They were in a bit of a jam in that they had one particularly strong product but didn’t have a sales force, so they acquired a company in the US to get them a sales force. He could see this was going to drop their earnings, so he sold his position.

COMMENT
COMMENT
November 10, 2014

Have a significant drug in the US that is doing extremely well. This is kind of growth by acquisition, but is interesting because in a lot of cases there really isn't an open bidding process for some of the drugs that come up for sale. It's all about personal relationships and the CEO of this company has some pretty good contacts. Earnings are expected to be pretty much unchanged in 2015. The real key is, can they acquire more drugs in order to grow.

Show full opinionHide full opinion

Have a significant drug in the US that is doing extremely well. This is kind of growth by acquisition, but is interesting because in a lot of cases there really isn't an open bidding process for some of the drugs that come up for sale. It's all about personal relationships and the CEO of this company has some pretty good contacts. Earnings are expected to be pretty much unchanged in 2015. The real key is, can they acquire more drugs in order to grow.

TOP PICK
TOP PICK
October 24, 2014

We are in an environment right now where pharmaceutical companies are very hot commodities. You either have to acquire things or you have to be acquired. This company is attractive in both respects. Have a great lead drug for teenage acne which is doing very well. Also, have a lot of cash. This could simultaneously be a very attractive acquisition or they could turn around and use that cash to buy other things in their product offering. They have a lot of options right now. His guess is that we are going to get reconciliation one way or another in the next six months. They are either going to buy a bunch of stuff or going to get a big pop in their rating or get taken out by somebody at a higher price. Trading at 13X earnings with about a 35% ROE.

Show full opinionHide full opinion

We are in an environment right now where pharmaceutical companies are very hot commodities. You either have to acquire things or you have to be acquired. This company is attractive in both respects. Have a great lead drug for teenage acne which is doing very well. Also, have a lot of cash. This could simultaneously be a very attractive acquisition or they could turn around and use that cash to buy other things in their product offering. They have a lot of options right now. His guess is that we are going to get reconciliation one way or another in the next six months. They are either going to buy a bunch of stuff or going to get a big pop in their rating or get taken out by somebody at a higher price. Trading at 13X earnings with about a 35% ROE.

PAST TOP PICK
PAST TOP PICK
August 6, 2014

(A Top Pick July 18/13. Up 56.25%.) The reports that are coming out are extremely favourable.

Show full opinionHide full opinion

(A Top Pick July 18/13. Up 56.25%.) The reports that are coming out are extremely favourable.

BUY
BUY
June 19, 2014

(Market Call Minute.) Has been trading sideways for about a year, but the ROE is really, really high. Have a lot of cash, and he thinks they are going to buy something soon. Stock is firming up nicely.

Show full opinionHide full opinion

(Market Call Minute.) Has been trading sideways for about a year, but the ROE is really, really high. Have a lot of cash, and he thinks they are going to buy something soon. Stock is firming up nicely.

PAST TOP PICK
PAST TOP PICK
June 4, 2014

(A Top Pick July 18/13. Up 30.07%.) This pick was based on the announcement that somebody was going to go into production eventually of its main line. (See Top Picks.)

Show full opinionHide full opinion

(A Top Pick July 18/13. Up 30.07%.) This pick was based on the announcement that somebody was going to go into production eventually of its main line. (See Top Picks.)

HOLD
HOLD
March 18, 2014

Over the last 12 months, this has had one of the weirdest trading patterns on the TSX. It sort of trades between $7 and $9 with no apparent reason. Its lead drug down in the US is doing great. Recent numbers were spectacular. He is meeting with management in a couple of days and wants to question what is happening with the rest of the company and what are they doing to develop the rest of the business. Wants to know what they have to do to get their lead drug moving in other countries, and with the phenomenal cash flows coming in, what are they doing to get other drugs going, etc. If you can buy this under $7.50, it is a very good buy.

Show full opinionHide full opinion

Over the last 12 months, this has had one of the weirdest trading patterns on the TSX. It sort of trades between $7 and $9 with no apparent reason. Its lead drug down in the US is doing great. Recent numbers were spectacular. He is meeting with management in a couple of days and wants to question what is happening with the rest of the company and what are they doing to develop the rest of the business. Wants to know what they have to do to get their lead drug moving in other countries, and with the phenomenal cash flows coming in, what are they doing to get other drugs going, etc. If you can buy this under $7.50, it is a very good buy.

WAIT
WAIT
January 3, 2014

Pharmaceuticals tend to gain from about July through to October. This is now consolidating and the chart shows a bit of a triangle pattern and it depends on which way it goes. Since we’re out of the period of seasonal strength, he would expect this to break to the downside. This is one you would buy on weakness as we get into June, July and August.

Show full opinionHide full opinion

Pharmaceuticals tend to gain from about July through to October. This is now consolidating and the chart shows a bit of a triangle pattern and it depends on which way it goes. Since we’re out of the period of seasonal strength, he would expect this to break to the downside. This is one you would buy on weakness as we get into June, July and August.

BUY
BUY
December 24, 2013

(Market Call Minute) Volatile but high ROE and he thinks you will see big numbers out of it in 2014.

Show full opinionHide full opinion

(Market Call Minute) Volatile but high ROE and he thinks you will see big numbers out of it in 2014.

BUY
BUY
November 6, 2013

(Market Call Minute.) Very volatile name. A generic drug manufacturer.

Show full opinionHide full opinion

(Market Call Minute.) Very volatile name. A generic drug manufacturer.

DON'T BUY
DON'T BUY
October 25, 2013

Have a couple of products that are coming out to market and one of them has very good potential and they have three-year exclusivity with the FDA. The problem is that a couple of weeks ago Watson Pharmaceutica challenged that drug with a generic version and the market freaked out a little. Valuation is pretty high as there are high expectations and now the risk has increased. Likes the company, management and what they are doing but doesn’t think there is a need to be involved with this one.

Show full opinionHide full opinion

Have a couple of products that are coming out to market and one of them has very good potential and they have three-year exclusivity with the FDA. The problem is that a couple of weeks ago Watson Pharmaceutica challenged that drug with a generic version and the market freaked out a little. Valuation is pretty high as there are high expectations and now the risk has increased. Likes the company, management and what they are doing but doesn’t think there is a need to be involved with this one.

BUY
BUY
October 18, 2013

A lead drug (Acne Drug) is gaining great market share in the States but a competitor filed to launch a generic. This process will take years to work through the courts so their patent gives them protection. A bit of a small worry but he holds it.

Show full opinionHide full opinion

A lead drug (Acne Drug) is gaining great market share in the States but a competitor filed to launch a generic. This process will take years to work through the courts so their patent gives them protection. A bit of a small worry but he holds it.

Showing 1 to 15 of 22 entries

Cipher Pharmaceuticals Inc.(CPHR-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Cipher Pharmaceuticals Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Cipher Pharmaceuticals Inc.(CPHR-Q) Frequently Asked Questions

What is Cipher Pharmaceuticals Inc. stock symbol?

Cipher Pharmaceuticals Inc. is a OTC stock, trading under the symbol CPHR-Q on the (). It is usually referred to as or CPHR-Q

Is Cipher Pharmaceuticals Inc. a buy or a sell?

In the last year, there was no coverage of Cipher Pharmaceuticals Inc. published on Stockchase.

Is Cipher Pharmaceuticals Inc. a good investment or a top pick?

Cipher Pharmaceuticals Inc. was recommended as a Top Pick by James Hodgins on 2019-12-30. Read the latest stock experts ratings for Cipher Pharmaceuticals Inc..

Why is Cipher Pharmaceuticals Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Cipher Pharmaceuticals Inc. worth watching?

0 stock analyst on Stockchase covered Cipher Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.

What is Cipher Pharmaceuticals Inc. stock price?

On , Cipher Pharmaceuticals Inc. (CPHR-Q) stock closed at a price of $.